Cargando…

Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score

IgA nephropathy (IgAN) is a common cause of end-stage renal disease (ESRD) in Asia. In this study, based on a large cohort of Chinese patients with IgAN, we aim to identify independent predictive factors associated with disease progression to ESRD. We collected retrospective clinical data and renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jingyuan, Kiryluk, Krzysztof, Wang, Weiming, Wang, Zhaohui, Guo, Shanmai, Shen, Pingyan, Ren, Hong, Pan, Xiaoxia, Chen, Xiaonong, Zhang, Wen, Li, Xiao, Shi, Hao, Li, Yifu, Gharavi, Ali G., Chen, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375310/
https://www.ncbi.nlm.nih.gov/pubmed/22719981
http://dx.doi.org/10.1371/journal.pone.0038904
_version_ 1782235750782205952
author Xie, Jingyuan
Kiryluk, Krzysztof
Wang, Weiming
Wang, Zhaohui
Guo, Shanmai
Shen, Pingyan
Ren, Hong
Pan, Xiaoxia
Chen, Xiaonong
Zhang, Wen
Li, Xiao
Shi, Hao
Li, Yifu
Gharavi, Ali G.
Chen, Nan
author_facet Xie, Jingyuan
Kiryluk, Krzysztof
Wang, Weiming
Wang, Zhaohui
Guo, Shanmai
Shen, Pingyan
Ren, Hong
Pan, Xiaoxia
Chen, Xiaonong
Zhang, Wen
Li, Xiao
Shi, Hao
Li, Yifu
Gharavi, Ali G.
Chen, Nan
author_sort Xie, Jingyuan
collection PubMed
description IgA nephropathy (IgAN) is a common cause of end-stage renal disease (ESRD) in Asia. In this study, based on a large cohort of Chinese patients with IgAN, we aim to identify independent predictive factors associated with disease progression to ESRD. We collected retrospective clinical data and renal outcomes on 619 biopsy-diagnosed IgAN patients with a mean follow-up time of 41.3 months. In total, 67 individuals reached the study endpoint defined by occurrence of ESRD necessitating renal replacement therapy. In the fully adjusted Cox proportional hazards model, there were four baseline variables with a significant independent effect on the risk of ESRD. These included: eGFR [HR = 0.96(0.95–0.97)], serum albumin [HR = 0.47(0.32–0.68)], hemoglobin [HR = 0.79(0.72–0.88)], and SBP [HR = 1.02(1.00–1.03)]. Based on these observations, we developed a 4-variable equation of a clinical risk score for disease progression. Our risk score explained nearly 22% of the total variance in the primary outcome. Survival ROC curves revealed that the risk score provided improved prediction of ESRD at 24th, 60th and 120th month of follow-up compared to the three previously proposed risk scores. In summary, our data indicate that IgAN patients with higher systolic blood pressure, lower eGFR, hemoglobin, and albumin levels at baseline are at a greatest risk of progression to ESRD. The new progression risk score calculated based on these four baseline variables offers a simple clinical tool for risk stratification.
format Online
Article
Text
id pubmed-3375310
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33753102012-06-20 Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score Xie, Jingyuan Kiryluk, Krzysztof Wang, Weiming Wang, Zhaohui Guo, Shanmai Shen, Pingyan Ren, Hong Pan, Xiaoxia Chen, Xiaonong Zhang, Wen Li, Xiao Shi, Hao Li, Yifu Gharavi, Ali G. Chen, Nan PLoS One Research Article IgA nephropathy (IgAN) is a common cause of end-stage renal disease (ESRD) in Asia. In this study, based on a large cohort of Chinese patients with IgAN, we aim to identify independent predictive factors associated with disease progression to ESRD. We collected retrospective clinical data and renal outcomes on 619 biopsy-diagnosed IgAN patients with a mean follow-up time of 41.3 months. In total, 67 individuals reached the study endpoint defined by occurrence of ESRD necessitating renal replacement therapy. In the fully adjusted Cox proportional hazards model, there were four baseline variables with a significant independent effect on the risk of ESRD. These included: eGFR [HR = 0.96(0.95–0.97)], serum albumin [HR = 0.47(0.32–0.68)], hemoglobin [HR = 0.79(0.72–0.88)], and SBP [HR = 1.02(1.00–1.03)]. Based on these observations, we developed a 4-variable equation of a clinical risk score for disease progression. Our risk score explained nearly 22% of the total variance in the primary outcome. Survival ROC curves revealed that the risk score provided improved prediction of ESRD at 24th, 60th and 120th month of follow-up compared to the three previously proposed risk scores. In summary, our data indicate that IgAN patients with higher systolic blood pressure, lower eGFR, hemoglobin, and albumin levels at baseline are at a greatest risk of progression to ESRD. The new progression risk score calculated based on these four baseline variables offers a simple clinical tool for risk stratification. Public Library of Science 2012-06-14 /pmc/articles/PMC3375310/ /pubmed/22719981 http://dx.doi.org/10.1371/journal.pone.0038904 Text en Xie et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Xie, Jingyuan
Kiryluk, Krzysztof
Wang, Weiming
Wang, Zhaohui
Guo, Shanmai
Shen, Pingyan
Ren, Hong
Pan, Xiaoxia
Chen, Xiaonong
Zhang, Wen
Li, Xiao
Shi, Hao
Li, Yifu
Gharavi, Ali G.
Chen, Nan
Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score
title Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score
title_full Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score
title_fullStr Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score
title_full_unstemmed Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score
title_short Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score
title_sort predicting progression of iga nephropathy: new clinical progression risk score
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375310/
https://www.ncbi.nlm.nih.gov/pubmed/22719981
http://dx.doi.org/10.1371/journal.pone.0038904
work_keys_str_mv AT xiejingyuan predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT kirylukkrzysztof predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT wangweiming predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT wangzhaohui predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT guoshanmai predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT shenpingyan predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT renhong predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT panxiaoxia predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT chenxiaonong predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT zhangwen predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT lixiao predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT shihao predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT liyifu predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT gharavialig predictingprogressionofiganephropathynewclinicalprogressionriskscore
AT chennan predictingprogressionofiganephropathynewclinicalprogressionriskscore